• 1
    Adam V, St-Pierre Y, Fautrel B, Clarke AE, Duffy CM, Penrod JR. What is the impact of adolescent arthritis and rheumatism? Evidence from a national sample of Canadians. J Rheumatol 2005; 32: 35461.
  • 2
    Kimura Y, Walco GA. Treatment of chronic pain in pediatric rheumatic disease. Nat Clin Pract Rheumatol 2007; 3: 2108.
  • 3
    Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007; 369: 76778.
  • 4
    Hazen AC, Smith FJ, Taylor KM, Rawcliffe C, Medcalf L, Keady S. Paediatric infliximab therapy: patients' and parents' perspectives on treatment options. Paediatr Perinat Drug Ther 2008; 8: 17781.
  • 5
    Jones F, Rodger S, Broderick S, de Monte R. Living with juvenile idiopathic arthritis: parents' experiences of treatment regimens and home exercise programmes. Br J Occup Ther 2009; 72: 24958.
  • 6
    Minden K. What are the costs of childhood-onset rheumatic disease? Best Pract Res Clin Rheumatol 2006; 20: 22340.
  • 7
    Costa V, Ungar WJ, Hancock R. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a health technology assessment. Toronto: The Hospital for Sick Children; 2010.
  • 8
    Guthrie B, Rouster-Stevens KA, Reynolds SL. Review of medications used in juvenile rheumatoid arthritis. Pediatr Emerg Care 2007; 23: 3846.
  • 9
    Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005; 294: 167184.
  • 10
    Hayward K, Wallace CA. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009; 11: 216.
  • 11
    Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63: 46582.
  • 12
    Ungar WJ, Costa V, Hancock-Howard R, Feldman BM, Laxer RM. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken) 2011; 63: 1119.
  • 13
    Brunner HI, Ravelli A. Developing outcome measures for paediatric rheumatic diseases. Best Pract Res Clin Rheumatol 2009; 23: 60924.
  • 14
    Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 12029.
  • 15
    Sawhney S, Agarwal M. Outcome measures in pediatric rheumatology. Indian J Pediatr 2010; 77: 11839.
  • 16
    Tucker LB. Outcome measures in childhood rheumatic diseases. Curr Rheumatol Rep 2000; 2: 34954.
  • 17
    Selvaag AM, Flato B, Lien G, Sorskaar D, Vinje O, Forre O. Measuring health status in early juvenile idiopathic arthritis: determinants and responsiveness of the Child Health Questionnaire. J Rheumatol 2003; 30: 160210.
  • 18
    Consolaro A, Vitale R, Pistorio A, Lattanzi B, Ruperto N, Malattia C, et al. Physicians' and parents' ratings of inactive disease are frequently discordant in juvenile idiopathic arthritis. J Rheumatol 2007; 34: 17736.
  • 19
    Janse AJ, Sinnema G, Uiterwaal CS, Kimpen JL, Gemke RJ. Quality of life in chronic illness: perceptions of parents and paediatricians. Arch Dis Child 2005; 90: 48691.
  • 20
    Sztajnbok F, Coronel-Martinez DL, Diaz-Maldonado A, Novarini C, Pistorio A, Viola S, et al. Discordance between physician's and parent's global assessments in juvenile idiopathic arthritis. Rheumatology (Oxford) 2007; 46: 1415.
  • 21
    Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 2008; 6: 114.
  • 22
    Chiou CF, Weisman M, Sherbourne CD, Reyes C, Dylan M, Ofman J, et al. Measuring preference weights for American College of Rheumatology response criteria for patients with rheumatoid arthritis. J Rheumatol 2005; 32: 23269.
  • 23
    Constantinescu F, Goucher S, Weinstein A, Smith W, Fraenkel L. Understanding why rheumatoid arthritis patient treatment preferences differ by race. Arthritis Rheum 2009; 61: 4138.
  • 24
    Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR. Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis 2004; 63: 13728.
  • 25
    Goodacre LJ, Goodacre JA. Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease-modifying medication. Rheumatology (Oxford) 2004; 43: 5836.
  • 26
    Sanderson T, Calnan M, Morris M, Richards P, Hewlett S. The impact of patient-perceived restricted access to anti-TNF therapy for rheumatoid arthritis: a qualitative study. Musculoskeletal Care 2009; 7: 194209.
  • 27
    Scarpato S, Antivalle M, Favalli EG, Nacci F, Frigelli S, Bartoli F, et al. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis: results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford) 2010; 49: 28994.
  • 28
    Taylor P, Manger B, Alvaro-Gracia J, Johnstone R, Gomez-Reino J, Eberhardt E, et al. Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res 2010; 38: 121324.
  • 29
    Von Muhlen CA, Neto DZ. Treatment of rheumatoid arthritis using anti-TNF therapy: patients view. Rev Bras Med 2005; 62: 829.
  • 30
    Barron AC, Lee TL, Taylor J, Moore T, Passo MH, Graham TB, et al. Feasibility and construct validity of the parent willingness-to-pay technique for children with juvenile idiopathic arthritis. Arthritis Rheum 2004; 51: 899908.
  • 31
    Hensher DA, Rose JM, Greene WH. Applied choice analysis: a primer. Cambridge: Cambridge University Press; 2005.
  • 32
    Bridges JF. Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Appl Health Econ Health Policy 2003; 2: 21324.
  • 33
    Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ 2000; 320: 15303.
  • 34
    Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health: a checklist. A report of the ISPOR good research practices for conjoint analysis task force. Value Health 2011; 14: 40313.
  • 35
    Lancaster K. Consumer demand: a new approach. New York: Columbia University Press; 1971.
  • 36
    Kuhfeld WF. Marketing research methods in SAS. Cary (NC): SAS Institute; 2010.
  • 37
    Huber J, Zwerina K. The importance of utility balance in efficient choice designs. J Marketing Res 1996; 33: 30717.
  • 38
    Ryan M, Watson V, Entwistle V. Rationalising the ‘irrational’: a think aloud study of discrete choice experiment responses. Health Econ 2009; 18: 32136.
  • 39
    Sculpher M, Gafni A. Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Health Econ 2001; 10: 31724.
  • 40
    Van Til JA, Stiggelbout AM, Ijzerman MJ. The effect of information on preferences stated in a choice-based conjoint analysis. Patient Educ Couns 2009; 74: 26471.
  • 41
    McFadden D. Conditional logit analysis of qualitative choice behavior. In: Zarembka P, editor. Frontiers in econometrics. New York: Academic Press; 1974. p. 10542.
  • 42
    Bech M, Gyrd-Hansen D. Effects coding in discrete choice experiments. Health Econ 2005; 14: 107983.
  • 43
    Hancock R. An economic evaluation of teratology information services. Toronto: University of Toronto; 2010.
  • 44
    Louviere J, Hensher DA, Swait JD. Stated choice models: analysis and application. Cambridge: Cambridge University Press; 2000.
  • 45
    Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user's guide. Pharmacoeconomics 2008; 26: 66177.